Jed Litwiniuk, MHA
Healthcare Executive and Corporate Finance Professional. Experience as head of M&A of Lux Med (the largest healthcare provider in CEE), Investment Director at Enterprise Venture Fund and PZU. CEO of orthopedics and spine surgery inpatient clinic (CM Gamma). Co-founder of Picket Pharmaceuticals, NYC based start-up. Executive MHA at Columbia University Mailman School of Public Health
Uwe Tigör, MD, MHA
Extensive marketing and product launch experience as Chief Medical Officer and Medical Director in healthcare marketing and communications agencies from IPG, WPP, HAVAS Health to InventivHealth; consultant to Pharmaceutical Industry. Medical training in EU and US, MD from Humboldt University, Berlin. Cardiovascular research experience including a research fellowship at Mount Sinai Hospital, NY. MHA candidate at Columbia University Mailman School of Public Health
Dawid Chabowski, PhD
Science and Operational Manager
Trained biomedical scientist with experience in basic science research in areas of cardiovascular physiology, microvascular function and lipid signaling. With research experiences from institutions such as St. John’s University, Wake Forest University, and Mayo Clinic, he received his PhD from the Department of Pharmacology and Toxicology at the Medical College of Wisconsin
Andrzej Domański, CFA
Capital Markets Advisor
Extensive equity market experience as Equity Analyst, Fund Manager and Head of Fund Management at Noble Funds TFI. Former Board Member of Eques Investment TFI. At Auxilius in charge of Investor Relations and Fundraising.
Tom A. Sigambris, MSc
GMP and Regulatory Compliance Officer
Regulatory and Quality Professional in the biopharmaceutical industry under CGMP regulations. Over 25 years of experience in management of all aspects of quality assurance (QA/QC) functions and regulatory functions in start-up, mid-sized and global biopharmaceutical facilities under FDA and EMA regulations. Expertise in the CMC section of NDA, ANDA and BLA submissions. Experience with FDA communications and issue resolution between industry and the FDA.
Paul A. Laskar, PhD
Pharmacuetical Development Expert
Dr. Paul Laskar has almost 40 years of experience focusing on pharmaceutical development and CMC issues of dermatological, ophthalmic, oral, and other sterile drug products. His career in industry began with Allergan where he led the CMC efforts for their first beta-blocker leading to a successful NDA and later their first topical retinoid leading to its IND for acne & psoriasis. Later with Santen-US, as head of pharmaceutical development he brought 4 products to successful NDA approvals and an IND for Santen’s first prostanoid for glaucoma. Dr. Laskar earned a PhD in Pharmaceutical Sciences (Oregon State University) and BS & MS Pharmacy degrees (University of Illinois Medical Center).
Adjunct Professor at Columbia University Business School. Partner at CEO Coaching International; Board Of Directors & Founder, Chief Innovation Office at Aculyst (healthcare analytics company).
Len S. Smith
Chief IP Counsel
Over 20 years crafting and carrying out strategies for transactions and operations relating to innovative technologies and products. Structuring and negotiating technology, financing, and corporate deals, and other contracts; board, regulatory compliance, IP strategy. Formerly of Valeant, Medicis & Novo Nordisk. Mr. Smith holds a J.D. with honors from Washington University, undergraduate and graduate level technical degrees in biology, environmental science, and information systems management. Mr. Smith also completed internships with the Office of the Vice President of the United States, the U.S. Patent and Trademark Office, and the U.S. District Court for the Southern District of Illinois.
Prof. Michael Weber
Dr Michael Weber is a Professor of Medicine at Downstate College of Medicine of the State University of New York. He received his medical degree from Sydney University in Australia. His career has focused largely on hypertension and preventive cardiology. He has also been very much involved with new drug development going back to the beta blockers and through to the contemporary angiotensin receptor blockers. He is an author of over 500 articles in the peer-reviewed literature and has authored or edited 16 books. He was a founder of the American Society of Hypertension (ASH) and the ASH Hypertension Clinical Specialists Accreditation Program and has served as President of both those organizations.